LOW-VOLUME · FEMALE-LED
levomilnacipran Side Effects
levomilnacipran (also sold as Fetzima) is a LOW-VOLUME FAERS extract #463 of 524 by FAERS report count. Still opens on FEMALE-LED: 76% of sex-coded reports are female (1,310 F / 407 M).
Data updated 2026-05-15
- 1,858
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
levomilnacipran reporting skew - 76% of sex-coded reports are female (1,310 F / 407 M). Volume band LOW-VOLUME #463 of 524 by FAERS report count; caseload SIGNAL.
Thinner FAERS extract for levomilnacipran (Fetzima) (1,858 reports #463 of 524 by FAERS report count). 76% of sex-coded reports are female (1,310 F / 407 M). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2013–2025). Stamps SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
PAIN leads 210 of 1,858 reports
FEMALE-LED reporters · age peak 18-44
Female-led reporters (76% of sex-coded rows)
Age peak 18-44 (469 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (154 reports, 8.3%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| MATERNAL EXPOSURE DURING PREGNANCY | 91 |
| CONDITION AGGRAVATED | 89 |
| OVERLAP SYNDROME | 73 |
| HYPOAESTHESIA | 29 |
| VOMITING | 29 |
| ABDOMINAL PAIN UPPER | 27 |
| DEATH | 26 |
| MEMORY IMPAIRMENT | 26 |
| PARAESTHESIA | 26 |
| RHEUMATOID ARTHRITIS | 26 |
| STOMATITIS | 26 |
| EPILEPSY | 25 |
| GASTROOESOPHAGEAL REFLUX DISEASE | 25 |
| MIGRAINE | 25 |
| PAIN | 25 |
| RHEUMATOID FACTOR POSITIVE | 25 |
Reactions in Hospitalization Reports
Hospitalization mid-share (283, 15.2%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| VOMITING | 43 |
| PAIN | 39 |
| HYPOAESTHESIA | 38 |
| MEMORY IMPAIRMENT | 35 |
| CONDITION AGGRAVATED | 34 |
| HYPERTENSION | 33 |
| PARAESTHESIA | 33 |
| ABDOMINAL PAIN UPPER | 32 |
| CHEST PAIN | 32 |
| GASTROOESOPHAGEAL REFLUX DISEASE | 32 |
| DEPRESSION | 31 |
| DYSPNOEA | 31 |
| RASH | 31 |
| RHEUMATOID ARTHRITIS | 31 |
| MIGRAINE | 30 |
| STOMATITIS | 30 |
| TASTE DISORDER | 30 |
How to read levomilnacipran FAERS figures (SIGNAL · DEATH-HEAVY · HOSP-MID)
FAERS holds 1,858 voluntary reports linked to levomilnacipran (Fetzima), 2013-2025. Death is listed on 154 (8.3%). Hospitalization appears on 283 (15.2%). Top co-reported indication: Product Used For Unknown Indication.
Sparse extract - named reactions and FEMALE-LED skew still differ by drug; not a complete safety profile.
Read with levomilnacipran
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 1,831 FAERS cases (Δ 27 lighter vs levomilnacipran); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 1,829 FAERS cases (Δ 29 lighter vs levomilnacipran); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 1,890 FAERS cases (Δ 32 heavier vs levomilnacipran); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 1,797 FAERS cases (Δ 61 lighter vs levomilnacipran); DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 53.8 pp vs levomilnacipran's DEATH-HEAVY): CASELOAD · HOSP-MID.
levomilnacipran stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload SIGNAL and the label guide.